Med BioGene Inc. (MBI.V) Wednesday reported a first quarter loss of $121 thousand, narrower than $197 thousand in the same quarter last year. On a per share basis, earnings were breakeven, flat with last year.
MBI did not incur any research and development expenses throughout the quarter, as its partner Precision Therapeutics, Inc., was responsible for all future costs associated with the development and commercialization of MBI's flagship test, LungExpress Dx, as announced in an agreement. In the prior year, Med BioGene has recorded R&D expenses of $42 thousand.
General and administrative expenses for the quarter increased 13 percent to $121 thousand from $107 thousand last year.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.